Collectively, these results demonstrate that RSK3/IκBα binding causes IκBα phosphorylation, resulting in NF-κB activation, and suggest that RSK3/IκBα binding could be a target for breast cancer treatment. This evidence concerns the gene NFKB1 and breast cancer.